Drug intelligence / Profile preview

BR010

Development stage: Preclinical
Lead developer: Brise Pharmaceuticals

Overview

BR010 is an early-stage therapeutic candidate under development by Brise Pharmaceuticals for the treatment of acute and chronic pain. Currently in the discovery phase, the specific biological target and molecular modality (e.g., small molecule or biologic) have not been disclosed by the developer. It represents part of Brise's expanding pipeline in the pain and migraine therapeutic areas, which includes other assets targeting CGRP.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on BR010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR010.

Explore the full profile